Drug Profile
USRP 003
Alternative Names: USRP-003Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Kao Corporation
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nocturia
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Nocturia(Prevention, In volunteers) in Japan (PO, Pill)
- 24 Jul 2019 Kao Corporation completes a phase-I clinical trial in Nocturia (Prevention, In volunteers) in Japan (UMIN000033923)
- 02 Sep 2018 Phase-I clinical trials in Nocturia (Prevention, In volunteers) in Japan (PO) (UMIN000033923)